Clinical Trial Update: Safety and Tolerability of a Single Dose of FCM vs. Standard of Care in Treating Iron Deficiency Anemia [Phase 3]

View source ↗

Summary

Phase 3 trial comparing a single dose of ferric carboxymaltose (FCM) to standard of care for iron deficiency anemia; safety and tolerability results reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iron Deficiency Anemia

Drugs mentioned

• Ferric carboxymaltose (ferric carboxymaltose)

Snippet

Sponsor: American Regent, Inc. | Conditions: Anemia | Phase 3 | Status: COMPLETED | Results posted: 2013-11-25